Cell line development (CLD) on the Beacon® optofluidic system enables selection of the best production cell lines with >99% monoclonality assurance in just days. The new Opto™ CLD 2.0 workflow extends these capabilities to allow (1) enrichment of rare cell populations, (2) on-chip titer measurements for traditional and non-traditional antibody molecules, and (3) efficient recovery of top clones for scale-up.